BofA analyst Jason Zemansky reinstated coverage of Esperion with a Neutral rating and $8 price target. Initial sales of the company’s novel cholesterol lowering agent bempedoic acid have "underwhelmed," and a major inflection is unlikely anytime soon, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ESPR:
